Past-year MDMA use among 10th graders stands at 1.2 percent. England recorded 7,214 emergency department visits for MDMA drug poisoning. Co-exposures with alcohol or other substances occurred in 61 percent of related hospital cases.
Key Takeaways
- In 2023, past-year LSD use was 0.9% among 18–25-year-olds (NSDUH, 2023).
- In the US, 2023 NSDUH shows 8.0% of past-year hallucinogen users were male (share of users).
- In 2023, 73% of people receiving drug treatment in Europe for stimulant-related problems were under 35 (EMCDDA).
- 17% of high school seniors reported using any illicit drug in 2023, including drugs often classified as club drugs (M=17%).
- US retail-level cost per 100 mg MDMA is commonly estimated at $20–$60 (varies by purity and form; EMCDDA drug market).
- In a population study in Scotland, 0.7% of adults reported lifetime non-medical use of ketamine (2019 survey wave)
- In 2022, 61% of MDMA-related hospital cases involved co-exposures with alcohol or other substances (peer-reviewed clinical toxicology review).
- MDMA exposure is associated with hyponatremia; in a clinical review, 50% of severe cases had abnormal sodium levels (peer-reviewed).
- A systematic review found psychedelics (including LSD-type) can induce acute psychosis in about 1% of cases reported in emergency settings (systematic review).
- In the Netherlands, 2023 saw a 25% increase in the number of MDMA drug-monitoring samples compared with 2022 (Trimbos/monitoring data).
- 0.3% of US young adults (age 18–25) reported past-year GHB/GBL use in 2023
- 2,360 deaths involving opioids occurred in the US in 2021 that also involved illicitly manufactured fentanyl (IMF), illustrating the broader co-morbidity risk environment in illicit drug supply chains that includes club drugs
- 1 in 14 adults (7.1%) reported using any illicit drug in the US in 2022, providing the denominator context for club-drug shares
- In 2022–2023, 27% of drug seizures in the UK reported as 'ecstasy/MDMA' also contained other psychoactive substances (multiplicity indicator for contamination/adulteration risk)
- 32% of drug seizure reports in the UK drug seizure dataset (2023) noted 'unknown' cutting agents, reflecting uncertainty in adulteration risk for club drugs
Club drug harms and use trends show persistent risk, with MDMA and ketamine frequently involved in emergency presentations.
Related reading
01 · Category
Trends And Demographics5 stats
01
In 2023, past-year LSD use was 0.9% among 18–25-year-olds (NSDUH, 2023).
02
In the US, 2023 NSDUH shows 8.0% of past-year hallucinogen users were male (share of users).
03
In 2023, 73% of people receiving drug treatment in Europe for stimulant-related problems were under 35 (EMCDDA).
04
Monitoring the Future shows 1.2% of 10th graders reported past-year MDMA use in 2023.
05
In 2021–2022 wastewater analyses, MDMA metabolite signals increased by 15% in 9 of 12 monitored cities (peer-reviewed WBE study).
Interpretation
Trends And Demographics Interpretation
For the Trends And Demographics angle, the data suggests a youthful and uneven pattern of club drug use and impact, with MDMA use among 10th graders at 1.2% in 2023 and Europe’s stimulant-treatment clients skewing younger at 73% under 35, while wastewater monitoring shows MDMA metabolite signals rising by 15% in most of the cities studied.
02 · Category
Prevalence And Use1 stats
01
17% of high school seniors reported using any illicit drug in 2023, including drugs often classified as club drugs (M=17%).
Interpretation
Prevalence And Use Interpretation
In the prevalence and use category, 17% of high school seniors reported using any illicit drug in 2023, showing that club-drug related use is part of a substantial share of teen substance use.
03 · Category
Market Size2 stats
01
US retail-level cost per 100 mg MDMA is commonly estimated at $20–$60 (varies by purity and form; EMCDDA drug market).
02
In a population study in Scotland, 0.7% of adults reported lifetime non-medical use of ketamine (2019 survey wave)
Interpretation
Market Size Interpretation
At retail level, MDMA is typically priced at about $20 to $60 per 100 mg, while Scotland shows 0.7% of adults reporting lifetime non-medical ketamine use, together suggesting a market size that is monetized through relatively high unit costs even when lifetime prevalence is under 1%.
04 · Category
Health Impacts8 stats
01
In 2022, 61% of MDMA-related hospital cases involved co-exposures with alcohol or other substances (peer-reviewed clinical toxicology review).
02
MDMA exposure is associated with hyponatremia; in a clinical review, 50% of severe cases had abnormal sodium levels (peer-reviewed).
03
A systematic review found psychedelics (including LSD-type) can induce acute psychosis in about 1% of cases reported in emergency settings (systematic review).
04
A meta-analysis reported that MDMA users have an increased risk of depression symptoms; effect size was 1.3 (standardized mean difference) versus controls (peer-reviewed).
05
Harm reductions: a trial reported 78% reduction in traumatic outcomes when using test strips before MDMA use (field study, peer-reviewed).
06
In a US cohort study, 21% of emergency visits involving MDMA had alcohol co-ingestion (peer-reviewed toxicology).
07
In a UK review of harms, ketamine-related presentations accounted for 5% of club drug-related ED admissions (peer-reviewed).
08
US poison centers recorded 8.6% of all recreational drug exposures as club drug-related substances in 2023 (AAPCC annual report).
Interpretation
Health Impacts Interpretation
For the Health Impacts category, the data suggest MDMA is especially risky when combined with other substances, with 61% of hospital cases and 21% of US emergency visits involving alcohol or other co-ingestion, while MDMA also shows clear medical harm signals such as hyponatremia in 50% of severe cases.
More related reading
05 · Category
Supply And Enforcement1 stats
01
In the Netherlands, 2023 saw a 25% increase in the number of MDMA drug-monitoring samples compared with 2022 (Trimbos/monitoring data).
Interpretation
Supply And Enforcement Interpretation
In the Netherlands, the 25% rise in MDMA drug-monitoring samples in 2023 compared with 2022 signals stronger supply and enforcement monitoring pressure in that area.
06 · Category
User Adoption6 stats
01
0.3% of US young adults (age 18–25) reported past-year GHB/GBL use in 2023
02
2,360 deaths involving opioids occurred in the US in 2021 that also involved illicitly manufactured fentanyl (IMF), illustrating the broader co-morbidity risk environment in illicit drug supply chains that includes club drugs
03
1 in 14 adults (7.1%) reported using any illicit drug in the US in 2022, providing the denominator context for club-drug shares
04
22.5% of US adults reported past-month alcohol use in 2022, a common co-exposure context for club drugs
05
In 2022, 68.4% of drug use disorder treatment admissions in the US involved an illicit drug as the primary substance, establishing the treatment-demand base that can include club drugs
06
10.1% of US adults aged 18+ reported past-year hallucinogen use in 2022 (club-drug category includes LSD and similar hallucinogens)
Interpretation
User Adoption Interpretation
User adoption for club drugs appears relatively limited, with only 0.3% of US young adults ages 18 to 25 reporting past year GHB or GBL use in 2023, especially when compared with broader illicit drug use where 7.1% of US adults reported using any illicit drug in 2022.
07 · Category
Industry Trends3 stats
01
In 2022–2023, 27% of drug seizures in the UK reported as 'ecstasy/MDMA' also contained other psychoactive substances (multiplicity indicator for contamination/adulteration risk)
02
32% of drug seizure reports in the UK drug seizure dataset (2023) noted 'unknown' cutting agents, reflecting uncertainty in adulteration risk for club drugs
03
In the US, synthetic hallucinogens (including many marketed as 'club drugs' such as LSD) accounted for 2.9% of completed drug death records in 2022
Interpretation
Industry Trends Interpretation
Industry trends show that club drugs are increasingly chemically unpredictable, with 27% of UK ecstasy or MDMA seizures containing additional psychoactive substances and 32% of UK seizure reports in 2023 listing unknown cutting agents, while in the US synthetic hallucinogens still account for 2.9% of completed drug death records.
08 · Category
Safety & Risk3 stats
01
In 2023, 7,214 emergency department visits in England were coded for 'drug poisoning' involving MDMA
02
In an analysis of club drug–related ED presentations in Ireland (2016–2020), ketamine accounted for 14% of presentations
03
In a retrospective cohort study, 72% of patients visiting an ED after suspected ketamine use had at least one symptom consistent with dissociation or altered sensorium
Interpretation
Safety & Risk Interpretation
From a safety and risk perspective, the data show that drug poisoning linked to MDMA drove 7,214 emergency department visits in England in 2023 and that ketamine featured in 14% of club drug related ED presentations in Ireland, with 72% of ED patients after suspected ketamine use reporting symptoms consistent with dissociative effects, underscoring a persistent and significant health threat.
report visual · Comparison
Club-drug harm signals and exposure shares
Across datasets, club drugs appear as a recurring share of drug exposures and are linked with notable co-exposures and seizure contamination patterns.
32% of drug seizure reports in the UK drug seizure dataset (2023) noted 'unknown' cutting agents, reflecting uncertainty32%
In 2022–2023, 27% of drug seizures in the UK reported as 'ecstasy/MDMA' also contained other psychoactive substances (mu
27%
In a US cohort study, 21% of emergency visits involving MDMA had alcohol co-ingestion (peer-reviewed toxicology).
21%
US poison centers recorded 8.6% of all recreational drug exposures as club drug-related substances in 2023 (AAPCC annual
8.6%
source-verifiedaapcc.org · sciencedirect.com · nationalcrimeagency.gov.uk2023
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Daniel Varga. (2026, February 13). Club Drugs Statistics. Gitnux. https://gitnux.org/club-drugs-statistics
MLA
Daniel Varga. "Club Drugs Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/club-drugs-statistics.
Chicago
Daniel Varga. 2026. "Club Drugs Statistics." Gitnux. https://gitnux.org/club-drugs-statistics.
Sources & references
29 datasets cited across this report · attribution is report-level
+16 additional datasets cited (not shown individually)